Saturday, July 24
Shadow

The Alexion Takeover Is a Major Expansion for AstraZeneca. Why the Stock Is Down 7%. – Barrons

AstraZeneca has agreed to acquire Alexion Pharmaceuticals, setting the British drugmaker up to expand its footprint in rare diseases and immunology during a year in which the company has become a household name for developing a Covid-19 vaccine candidate with the University of Oxford.

As the market reacted to the news on Monday, share movements for the two companies diverged drastically, with AstraZeneca sinking in London trading while Alexion surged in the New York premarket.

The…

Leave a Reply

Your email address will not be published. Required fields are marked *